Skip to content
Head to head

Viking Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: VKTX · VRTX

Updated 2 minutes ago

1-year performance, rebased to 100

VKTX -35.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
VKTXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price24.77515.02
Change today-4.14%-1.08%
1-year return-27.7%+22.0%
Market cap$3.16B$130.58B
52-week range23.82 – 43.10412.27 – 568.67
Valuation
P/E (TTM)-4.5733.14
P/E percentile, own 5-yr range81st99th
P/B5.376.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.1915.32
Net profit (TTM)$-406.80M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-462.63M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership66.3%96.8%
Insider activity (12mo)36 buy / 14 sell28 buy / 22 sell
Short interest (% of float)18.9%1.9%
Analyst consensus94% buy / 6% hold (16)95% buy / 5% hold (21)
Analyst price target$94 (+278%)$624 (+21%)
StockVane view
StockVane Quant RatingE (14)C (68)
Company
Employees536,400
Founded20121989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.